IART
HealthcareIntegra LifeSciences Holdings Corporation
Key Drivers
- Margin rebound
- Stronger liquidity
- Negative FCF
AIAI Summary
IART has shifted from a weak-margin medtech laggard to a credible turnaround story after Q1 revenue upside, margin expansion, and raised FY2026 EPS guidance, but the investment now hinges on whether management can prove this earnings inflection is durable through sustained margin improvement and stronger free cash flow, since the recent stock re-rating already prices in much of the good news.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin rebound
- •Stronger liquidity
- •Negative FCF
IART's Q1 2026 rebound in margins and liquidity is encouraging, but persistent annual losses, negative free cash flow, and elevated leverage keep the investment case cautious.
Price Behavior
Key Price Behavior Insights:
- •Breakout strength
- •Rising support
- •Stretched move
IART broke out from a choppy base into a clear last month uptrend, holding above $13 with support at $13.20-$13.60, but the move is stretched and now faces resistance at $14.90.
Sharp jump from around $10.08 to the mid-$14s, followed by a quick pullback, signals elevated volatility risk
Sentiment & News
Key News Insights:
- •Q1 Beat
- •Leadership Shift
- •Debt Concerns
Integra's Q1 earnings beat, upgraded sentiment, and new leadership appointments point to improving near-term momentum, though debt and macro risks still matter.
The news is modestly positive for IART, with the earnings surprise and buy-rating upgrade likely supporting the stock despite lingering balance-sheet and market uncertainty
Similar Companies in Healthcare
Other companies in the same sector with AI ratings